Sumaiya Sharmeen counsels clients in complex IP litigation matters in the hardware, software, medical device, biotechnology, and pharmaceutical industries.Sumaiya is a member of the firm’s Intellectual Property Group. She applies her degrees in medical biophysics, genetics, and biotechnology to assist clients in intellectual property litigation matters, including trade secrets and patent litigation, preparing infringement and validity analysis, and serving as counsel in fact and expert depositions, motions, hearings, and jury trials. Sumaiya’s work in this area includes proceedings involving gene therapy, monoclonal antibodies, antibody-drug conjugates, manufacturing and purification process of recombinant proteins, and small molecule inhibitors.
Prior to joining the firm, Sumaiya was an attorney in Toronto, where she focused on IP litigation as well as strategic IP counseling. She has litigated before the state and federal trial courts on a wide-range of technologies, including biotechnology, pharmaceuticals, and information technology. In addition to her litigation practice, Sumaiya has advised clients on strategic transactional issues and patent licensing discussions.
Experience
Representing defendant Sandoz Inc. in a proceeding under the Affordable Care Act’s Biologics Price Competition and Innovation Act (BPCIA) to bring a biosimilar to an antibody product to market for osteoporosis and oncology indications.
Represented plaintiff Seagen (f/k/a Seattle Genetics) in an infringement action involving patents infringed by Daiichi’s Enhertu treatment. The jury rendered its verdict of willful infringement and no invalidity after less than two hours of deliberation, awarding the entire $41.8 million Seagen requested.
Represented plaintiff in a trade secret and breach of contract dispute with a former employee and a co-founder involving gene therapy for neurodenegerative diseases. Successfully obtained favorable outcome.